Related references
Note: Only part of the references are listed.A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC)
J. Chandra et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Human papillomavirus E6 and E7: What remains?
Arushi Vats et al.
TUMOUR VIRUS RESEARCH (2021)
Epigenetic modulation of immunotherapy and implications in head and neck cancer
Liye Zhou et al.
CANCER AND METASTASIS REVIEWS (2021)
A model of seven immune checkpoint-related genes predicting overall survival for head and neck squamous cell carcinoma
Daoliang Song et al.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY (2021)
Immunodiagnosis and Immunotherapeutics Based on Human Papillomavirus for HPV-Induced Cancers
Zhen Dong et al.
FRONTIERS IN IMMUNOLOGY (2021)
Oropharyngeal Squamous Cell Carcinoma With Discordant p16 and HPV mRNA Results Incidence and Characterization in a Large, Contemporary United States Cohort
Justin R. Shinn et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Biomarkers for Immunotherapy of Oral Squamous Cell Carcinoma: Current Status and Challenges
Alhadi Almangush et al.
FRONTIERS IN ONCOLOGY (2021)
Genomic and Molecular Profiling of Human Papillomavirus Associated Head and Neck Squamous Cell Carcinoma Treated with Immune Checkpoint Blockade Compared to Survival Outcomes
Hira Shaikh et al.
CANCERS (2021)
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Nancy Y Lee et al.
LANCET ONCOLOGY (2021)
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
Jong-Mu Sun et al.
LANCET (2021)
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
Thomas Powles et al.
LANCET ONCOLOGY (2021)
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
N. Colombo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma-Systematic review and meta-analysis
Jaimin J. Patel et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2020)
Biomarkers for immunotherapy response in head and neck cancer
Niki Gavrielatou et al.
CANCER TREATMENT REVIEWS (2020)
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
Matthew H. Taylor et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Impact of HPV E5 on viral life cycle via EGFR signaling
Naureen Ehsan Ilahi et al.
MICROBIAL PATHOGENESIS (2020)
Current Status of p16 Immunohistochemistry and HPV Testing in Fine Needle Aspiration Specimens of the Head and Neck
Jalal B. Jalaly et al.
ACTA CYTOLOGICA (2020)
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open -label phase III study
R. L. Ferris et al.
ANNALS OF ONCOLOGY (2020)
Cancer immunotherapy: Pros, cons and beyond
Shuzhen Tan et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Immune checkpoint signaling and cancer immunotherapy
Xing He et al.
CELL RESEARCH (2020)
DURTRERAD: A phase II open-label study evaluating feasibility and efficacy of durvalumab (D) and durvalumab and tremelimumab (DT) in combination with radiotherapy (RT) in non-resectable locally advanced HPV-negative HNSCC—Results of the preplanned feasibility interim analysis.
Konrad Friedrich Klinghammer et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Tumor Membrane Vesicle Vaccine Augments the Efficacy of Anti-PD1 Antibody in Immune Checkpoint Inhibitor-Resistant Squamous Cell Carcinoma Models of Head and Neck Cancer
Ramireddy Bommireddy et al.
VACCINES (2020)
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407
Luis Paz-Ares et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
An update on the immune landscape in lung and head and neck cancers
Jennifer W. Carlisle et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Onco-fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma
Ankur Sharma et al.
CELL (2020)
Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice
Hui-Ching Wang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2020)
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial
Jonathan D. Schoenfeld et al.
JAMA ONCOLOGY (2020)
Identification of prognostic aging-related genes associated with immunosuppression and inflammation in head and neck squamous cell carcinoma
Jing Yang et al.
AGING-US (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
Head and neck squamous cell carcinoma
Daniel E. Johnson et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
Pathology of HPV-Associated Head and Neck Carcinomas: Recent Data and Perspectives for the Development of Specific Tumor Markers
Xavier Sastre-Garau et al.
FRONTIERS IN ONCOLOGY (2020)
Impact of notch signaling on the prognosis of patients with head and neck squamous cell carcinoma
Gianluigi Grilli et al.
ORAL ONCOLOGY (2020)
Hallmarks of HPV carcinogenesis: The role of E6, E7 and E5 oncoproteins in cellular malignancy
Diogo Estevao et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2019)
Immunotherapy for Head and Neck Cancer
Felix Sim et al.
ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA (2019)
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use
Robert L. Ferris et al.
CLINICAL CANCER RESEARCH (2019)
Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade
B. R. Heath et al.
JOURNAL OF DENTAL RESEARCH (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
Robert Motzer et al.
LANCET ONCOLOGY (2019)
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Shuang Qin et al.
MOLECULAR CANCER (2019)
Novel Immunotherapy Combinations
Babar Bashir et al.
CURRENT ONCOLOGY REPORTS (2019)
DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients’ survival, immune cell infiltrates, mutational load, and interferon γ signature
Verena Sailer et al.
EBioMedicine (2019)
Immune checkpoint inhibitors win the 2018 Nobel Prize
Pei-Wei Huang et al.
BIOMEDICAL JOURNAL (2019)
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
Dan P. Zandberg et al.
EUROPEAN JOURNAL OF CANCER (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC The Phase 2 CONDOR Randomized Clinical Trial
Lillian L. Siu et al.
JAMA ONCOLOGY (2019)
Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance
Shu-Wei Chen et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2019)
Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer
Charu Aggarwal et al.
CLINICAL CANCER RESEARCH (2019)
Human Papillomavirus Testing in Head and Neck Carcinomas Guideline From the College of American Pathologists
James S. Lewis et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)
STINGel: Controlled release of a cyclic dinucleotide for enhanced cancer immunotherapy.
David G. Leach et al.
BIOMATERIALS (2018)
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
Ranee Mehra et al.
BRITISH JOURNAL OF CANCER (2018)
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma
Yuk Pheel Park et al.
ORAL ONCOLOGY (2018)
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
Robert L. Ferris et al.
ORAL ONCOLOGY (2018)
HPV-relatedness definitions for classifying HPV-related oropharyngeal cancer patient do impact on TNM classification and patients' survival
Miren Taberna et al.
PLOS ONE (2018)
Personalized vaccines for cancer immunotherapy
Ugur Sahin et al.
SCIENCE (2018)
The HPV E6/E7 Oncogenes: Key Factors for Viral Carcinogenesis and Therapeutic Targets
Karin Hoppe-Seyler et al.
TRENDS IN MICROBIOLOGY (2018)
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck The Active8 Randomized Clinical Trial
Robert L. Ferris et al.
JAMA ONCOLOGY (2018)
Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial
A. D. Colevas et al.
ANNALS OF ONCOLOGY (2018)
Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline
Carole Fakhry et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immunotherapy and Prevention of Pancreatic Cancer
Alexander H. Morrison et al.
TRENDS IN CANCER (2018)
Breast Cancer Immunotherapy: Facts and Hopes
Leisha A. Emens
CLINICAL CANCER RESEARCH (2018)
HPV 16 E5 oncoprotein is expressed in early stage carcinogenesis and can be a target of immunotherapy
Francesca Paolini et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)
Androgen deprivation and immunotherapy for the treatment of prostate cancer
Melissa Gamat et al.
ENDOCRINE-RELATED CANCER (2017)
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
Joshua Bauml et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch et al.
LANCET (2017)
Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer
Amanda Rosewell Shaw et al.
MOLECULAR THERAPY (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Unique DNA methylation signature in HPV-positive head and neck squamous cell carcinomas
Davide Degli Esposti et al.
GENOME MEDICINE (2017)
Human papillomavirus-related oropharyngeal cancer
M. Taberna et al.
ANNALS OF ONCOLOGY (2017)
The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia
Marta Sanchez-Martin et al.
BLOOD (2017)
Head and Neck Cancers-Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual
William M. Lydiatt et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft Rejection
Janin Chandra et al.
JOURNAL OF IMMUNOTHERAPY (2017)
Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy
Shari Pilon-Thomas et al.
CANCER RESEARCH (2016)
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Tanguy Y. Seiwert et al.
LANCET ONCOLOGY (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Oral cavity and oropharyngeal squamous cell carcinomaan update
Angela C. Chi et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Cancer immunotherapy: harnessing the immune system to battle cancer
Yiping Yang
JOURNAL OF CLINICAL INVESTIGATION (2015)
Immunology and Immunotherapy of Head and Neck Cancer
Robert L. Ferris
JOURNAL OF CLINICAL ONCOLOGY (2015)
Comprehensive genomic characterization of head and neck squamous cell carcinomas
Michael S. Lawrence et al.
NATURE (2015)
Epidemiology of Head and Neck Cancer
Eleni M. Rettig et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2015)
Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity
Biswanath Majumder et al.
NATURE COMMUNICATIONS (2015)
Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics
Stanleyson V. Hato et al.
CLINICAL CANCER RESEARCH (2014)
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
Liufu Deng et al.
IMMUNITY (2014)
Eurogin Roadmap: Comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix
Maura L. Gillison et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Human papillomavirus-stratified analysis of the prognostic role of miR-21 in oral cavity and oropharyngeal squamous cell carcinoma
Yoon Ho Ko et al.
PATHOLOGY INTERNATIONAL (2014)
Human papillomavirus detection and comorbidity: critical issues in selection of patients with oropharyngeal cancer for treatment De-escalation trials
M. M. Rietbergen et al.
ANNALS OF ONCOLOGY (2013)
Deciphering and Reversing Tumor Immune Suppression
Greg T. Motz et al.
IMMUNITY (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
A Phase 1 Safety Study of an IRX-2 Regimen in Patients With Squamous Cell Carcinoma of the Head and Neck
Scott M. Freeman et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2011)
Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx - TPF-C-HIT
Alexandra D. Jensen et al.
BMC CANCER (2011)
A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia
Apostolos Klinakis et al.
NATURE (2011)
Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1
Nishant Agrawal et al.
SCIENCE (2011)
The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Nicolas Stransky et al.
SCIENCE (2011)
HPV-associated head and neck cancer: a virus-related cancer epidemic
Shanthi Marur et al.
LANCET ONCOLOGY (2010)
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
K. Kian Ang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oropharyngeal squamous cell carcinoma: A unique disease on the rise?
Hester S. van Monsjou et al.
ORAL ONCOLOGY (2010)
Establishment and Characterization of a Novel Head and Neck Squamous Cell Carcinoma Cell Line USC-HN1
Daniel J. Liebertz et al.
HEAD & NECK ONCOLOGY (2010)
Effect of HPV-Associated p16INK4A Expression on Response to Radiotherapy and Survival in Squamous Cell Carcinoma of the Head and Neck
Pernille Lassen et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Global epidemiology of oral and oropharyngeal cancer
Saman Warnakulasuriya
ORAL ONCOLOGY (2009)
Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7
David Lindquist et al.
MOLECULAR ONCOLOGY (2007)
Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer:: Pooled analysis in the international head and neck cancer epidemiology consortium
Mia Hashibe et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Case-control study of human papillomavirus and oropharyngeal cancer
Gypsyamber D'Souza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking
Bhavna Kumar et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma
Lisa Licitra et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Share Paper
